Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study

INTRODUCTION: Interleukin-6 (IL-6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL-6Rα. In TARGET (NCT01709578), a phase 3 study in adults with moderate-to-severe RA and inadequate respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabay, Cem, Msihid, Jérôme, Zilberstein, Moshe, Paccard, Caroline, Lin, Yong, Graham, Neil M H, Boyapati, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856917/
https://www.ncbi.nlm.nih.gov/pubmed/29556418
http://dx.doi.org/10.1136/rmdopen-2017-000607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856917/
https://www.ncbi.nlm.nih.gov/pubmed/29556418
http://dx.doi.org/10.1136/rmdopen-2017-000607

Ejemplares similares